Vilde Yuli Stenberg

  • PhD Student; M.Sc
  • 22781224

Room J4029

 

Publications 2023

Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH (2023)
Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
Front Med (Lausanne), 9, 1051825
DOI 10.3389/fmed.2022.1051825, PubMed 36733936

Publications 2022

Li RG, Stenberg VY, Larsen RH (2022)
An Experimental Generator for Production of High-Purity 212Pb for Use in Radiopharmaceuticals
J Nucl Med, 64 (1), 173-176
DOI 10.2967/jnumed.122.264009, PubMed 35798556

Stenberg VY, Tornes AJK, Nilsen HR, Revheim ME, Bruland ØS, Larsen RH, Juzeniene A (2022)
Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001
Cancers (Basel), 14 (11)
DOI 10.3390/cancers14112784, PubMed 35681766

Tornes AJK, Stenberg VY, Larsen RH, Bruland ØS, Revheim ME, Juzeniene A (2022)
Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
Front Med (Lausanne), 9, 1058863
DOI 10.3389/fmed.2022.1058863, PubMed 36507500

Publications 2021

Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH (2021)
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
Cancers (Basel), 13 (4)
DOI 10.3390/cancers13040779, PubMed 33668474

Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A (2021)
Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094815, PubMed 34062920

Publications 2020

Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples
Appl Radiat Isot, 166, 109362
DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756

Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Curr Radiopharm, 13 (2), 130-141
DOI 10.2174/1874471013666200511000532, PubMed 32389119

Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer
J Labelled Comp Radiopharm, 63 (3), 129-143
DOI 10.1002/jlcr.3825, PubMed 31919866

Page visits: 2142